Literature DB >> 27206021

Morbidity and mortality of adult patients with congenital dyserythropoietic anemia type I.

Hanna Shalev1, Kaid Al-Athamen2, Itai Levi2, Aviva Levitas3, Hannah Tamary4.   

Abstract

Congenital dyserythropoietic anemia type I (CDAI) is a rare autosomal recessive disease characterized by macrocytic anemia, ineffective erythropoiesis, and secondary hemochromatosis. To better define the natural history of the disease among adult patients, we studied 32 Bedouin patients (median age 34 yr; range 21-60) all carrying the same CDAN1 founder mutation. Follow-up studies included complete blood count, blood chemistry, abdominal ultrasound, echocardiography, and T2*MRI. Main complications were due to anemia and ineffective erythropoiesis [osteoporosis (8/9, 89%), cholelithiasis (21/30, 70%), pulmonary arterial hypertension (PAH) (6/25, 24%)] and iron overload [hypothyroidism (9/24, 38%), and diabetes mellitus (6/32, 19%)]. T2* MRI revealed increased liver iron but no cardiac iron (13/13). Anemia improved in the majority of patients who underwent splenectomy (5/6). Three patients died (9%) at the age of 46-56 due to PAH (1) and sepsis (2). All previously underwent splenectomy. Analyzing both our patients and the 21 patients previously described by Heimpel et al. (Blood 107:334, 2006), we conclude that adults with CDA I suffer significant morbidity and mortality. Careful monitoring of iron overload and prompt iron chelation therapy is mandatory. Due to possible complications and inconsistent response to splenectomy α-interferon, transfusion therapy or stem cell transplantation should be considered as alternatives to this procedure in severely affected patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  congenital dyserythropoietic anemia; ineffective erythropoiesis; iron overload

Mesh:

Substances:

Year:  2016        PMID: 27206021     DOI: 10.1111/ejh.12778

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Codanin-1 mutations engineered in human erythroid cells demonstrate role of CDAN1 in terminal erythroid maturation.

Authors:  Zachary C Murphy; Michael R Getman; Jaquelyn A Myers; Kimberly N Burgos Villar; Emily Leshen; Ryo Kurita; Yukio Nakamura; Laurie A Steiner
Journal:  Exp Hematol       Date:  2020-10-16       Impact factor: 3.084

Review 2.  The congenital dyserythropoieitic anemias: genetics and pathophysiology.

Authors:  Richard King; Patrick J Gallagher; Rami Khoriaty
Journal:  Curr Opin Hematol       Date:  2021-12-24       Impact factor: 3.218

3.  Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).

Authors:  Omar Niss; Robert B Lorsbach; Mikaela Berger; Satheesh Chonat; Morgan McLemore; David Buchbinder; Timothy McCavit; Linda G Shaffer; Jessica Simpson; Jeffrey H Schwartz; Jessica Meznarich; Myesa Emberesh; Katie G Seu; Wenying Zhang; Theodosia A Kalfa
Journal:  Blood Cells Mol Dis       Date:  2020-12-24       Impact factor: 3.039

4.  Recommendations regarding splenectomy in hereditary hemolytic anemias.

Authors:  Achille Iolascon; Immacolata Andolfo; Wilma Barcellini; Francesco Corcione; Loïc Garçon; Lucia De Franceschi; Claudio Pignata; Giovanna Graziadei; Dagmar Pospisilova; David C Rees; Mariane de Montalembert; Stefano Rivella; Antonella Gambale; Roberta Russo; Leticia Ribeiro; Jules Vives-Corrons; Patricia Aguilar Martinez; Antonis Kattamis; Beatrice Gulbis; Maria Domenica Cappellini; Irene Roberts; Hannah Tamary
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

Review 5.  The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.

Authors:  Noémi B A Roy; Christian Babbs
Journal:  Br J Haematol       Date:  2019-03-05       Impact factor: 6.998

Review 6.  Congenital Hemolytic Anemias: Is There a Role for the Immune System?

Authors:  Anna Zaninoni; Elisa Fermo; Cristina Vercellati; Anna Paola Marcello; Wilma Barcellini; Paola Bianchi
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.